AGP Executive Report
Last update: 3 hours agoClinical Trials Acceleration: The FDA opened applications for its Expedited IND Pilot (Operation TrialBlazer), aiming to speed first-in-human timelines via sponsor–qualified research institution pairs and iterative IND component review. AI in Drug Development: A Tufts CSDD benchmarking study found sourcing model choice doesn’t consistently drive trial performance; operating model design and partner coordination do. Patient-Centered Execution: uMotif CEO Andrea Valente argues AI can’t replace the patient-site relationship—trial success depends on mapping the full patient journey and educating both sides together. Rare Disease Evidence Engineering: New guidance highlights building submission-grade real-world evidence from the start when registries don’t exist, with cohort and endpoint decisions treated as design inputs. Pharma Approvals: FDA cleared Lilly’s Olumiant for pediatric severe alopecia areata, expanding treatment options for adolescents. AI Infrastructure & Power: Analysts note AI data centers are pushing demand for on-site generation and new financing structures as grid connections lag. Applied AI in Industry: Universal Music Group named Òscar Celma SVP for Applied AI and Machine Learning, bringing Spotify-style AI features into global operations.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
